HER2-Positive Breast Cancer Market
Key Highlights
- According to SEER, the incidence rate of new breast cancer cases for HR+/HER2+ is 13.4 cases per 100,000 women, as compared to the 5.5 cases per 100,000 women for HR-/HER2+ breast cancer.
- HER2+ Breast Cancer epidemiology is segmented as Total HER2+ Breast Cancer Incident Cases of Breast Cancers, HER2+ Incident Cases of Breast Cancer, and HER2+ Breast Cancer Subtype-specific Incidence, HER2+ Breast Cancer Stage-specific Incidence, and HER2+ Breast Cancer Diagnosed and Treatable cases in the HER2+ Breast Cancer market report.
Request for unlock CAGR of HER2 Breast Cancer Market
DelveInsight's "HER2+ Breast Cancer — Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the HER2+ Breast Cancer, historical and forecasted epidemiology as well as the HER2+ Breast Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom and Japan.
The HER2+ Breast Cancer market report provides current treatment practices, emerging drugs, HER2+ Breast Cancer market share of the individual therapies, current and forecasted HER2+ Breast Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current HER2+ Breast Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, Spain, Italy, and France) and the United Kingdom
- Japan
Study Period: 2019–2032
HER2+ Breast Cancer Market Disease Understanding and Treatment Algorithm
The DelveInsight’s HER2+ Breast Cancer market report gives a thorough understanding of HER2+ Breast Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. HER2 (human epidermal growth factor receptor 2) is a protein that helps breast cancer cells grow quickly. Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein. But when there is a mutation in the gene that controls the HER2 protein, also known as erythroblastic oncogene B (ERBB2) gene, the body creates too many HER2 receptors, which results in uncontrollable breast cell growth and division. The most common signs of this indication are breast swelling, change in the shape of breast, skin irritation or dimpling, pain in the breast, redness or thickness of the breast skin.
The most common symptom of HER2+ breast cancer is the generation of Lump. Other symptoms involved are skin irritation or dimpling, discharge from the nipple, breast swelling, pain in the breast or nipple, redness or thickness of the nipple or breast skin, and a change in breast shape.
HER2+ Breast Cancer Diagnosis
Diagnosis of HER2-positive breast cancer is made by following recommended tests, such as the IHC (ImmunoHistoChemistry) test, the FISH (Fluorescence in situ hybridization) test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests use antibodies or DNA to stain the cancer cells.
HER2+ Breast Cancer Treatment
In general, treatment options may include surgery, HER2-directed therapy, endocrine therapy, and radiation therapy. The best combination of treatments, and the order in which to get them, can vary depending on the situation. Many women with HER2-positive breast cancer will get neoadjuvant chemotherapy first, along with medication that targets HER2 directly. Following surgery, these women will get additional (adjuvant) therapy with a HER2-directed medication.
HER2+ Breast Cancer Epidemiology
The HER2+ Breast Cancer epidemiology section provides insights about historical and current HER2+ Breast Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
- According to SEER, the incidence rate of new breast cancer cases for HR+/HER2+ is 13.4 cases per 100,000 women, as compared to the 5.5 cases per 100,000 women for HR-/HER2+ breast cancer.
- The disease epidemiology covered in the report provides historical as well as forecasted HER2+ Breast Cancer epidemiology [segmented as Total Incident Cases of Breast Cancers, HER2+ Incident Cases of Breast Cancer, Subtype-specific Incidence of Breast Cancer (HR+/HER2+ and HR-/HER2+), Stage-specific Incidence of HER2+ Breast Cancer, and Diagnosed and Treatable cases of HER2+ Breast Cancer] in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country Wise- HER2+ Breast Cancer Epidemiology
This section provides a glimpse of the HER2+ Breast Cancer epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Learn more about the evolving epidemiology trends and key developments: HER2-Positive Breast Cancer Epidemiology Forecast
HER2+ Breast Cancer Drug Chapters
The drug chapter segment of the HER2+ Breast Cancer report encloses the detailed analysis of HER2+ Breast Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the HER2+ Breast Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
HER2+ Breast Cancer Marketed Drugs
HERCEPTIN (trastuzumab): Genetech
Herceptin was first FDA approved in 1998 to treat HER2+ metastatic breast cancer. It can be used to treat both early-stage and advanced breast cancer.
PERJETA (pertuzumab): Genetech/Roche
It was first approved by the FDA in 2012 to treat HER2+ metastatic breast cancer. It is a HER2 monoclonal antibody that can be given with trastuzumab and chemo, either before or after surgery to treat early-stage breast cancer, or to treat advanced breast cancer. In December, 2017, the FDA granted regular approval to pertuzumab for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
Note: Detailed Current therapies assessment will be provided in the full report of HER2+ Breast Cancer
HER2+ Breast Cancer Emerging Drugs
BYL719 (alpelisib) is an investigational, orally bioavailable, alpha-specific PI3K inhibitor which is being developed by Novartis. PIK3CA somatic mutations in HER2-positive disease are frequent and represent approximately 30% of all HER2-positive and HR-positive tumors. In breast cancer cell lines harboring PIK3CA mutations, BYL719 has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects. In addition, cancer cell lines with PIK3CA mutations were more sensitive to BYL719 than those without the mutation across a broad range of different cancers.
SYD985 (Trastuzumab duocarmazine) is a novel HER2-targeting ADC that comprises an HER2 antibody, very similar to trastuzumab, conjugated via a cleavable linker to the alkylator duocarmycin. It is being developed by Byondis.
Note: Detailed emerging therapies assessment will be provided in the full report of HER2+ Breast Cancer
HER2+ Breast Cancer Market Outlook
The market comprises a variety of options for the treatment of HER-2 Positive Breast Cancer. Treatment, which is mainly categorized into pharmacological and non-pharmacological therapies. Systemic therapies are generally prescribed by a medical oncologist. Common ways to give systemic therapies include an intravenous (IV) tube or can be given orally.
The systemic therapies used for metastatic breast cancer include Targeted Therapy and Hormonal therapy (Endocrine therapy). Although the first-line treatment of metastatic breast cancer is mainly dependent on the receptor status, both estrogen and progesterone receptor status and HER2 receptor status should be tested. If the tumor represents both HER2-positive and estrogen receptor-positive then initial treatment may include hormonal therapy or a HER2-targeted therapy or both.
The introduction of anti-HER2 therapies for the treatment of patients with HER2-positive breast cancer has led to dramatic improvements in survival in both early and advanced settings. Despite, having currently available anti-HER2 therapies that have changed the natural history of HER2-positive breast cancer, new therapeutic options are necessary because the disease is essentially incurable in the metastatic setting and a relevant proportion of patients with early-stage disease still relapse in spite of the use of currently available therapies.
Key players such as Novartis, Byondis, Pfizer, Merck Sharp & Dohme, Seagen, Alphamab Oncology, Zymeworks/ALX Oncology and Roche along with few others are involved in developing therapies for HER-2+ Breast Cancer.
According to DelveInsight, HER2+ Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Analyst Commentary
- The pipeline of HER2+ Breast Cancer is very robust, many potential therapies are being investigated for the treatment of HER2+ Breast Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
- The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the HER2+ Breast Cancer market in the 7MM. Aside from that, the market size of HER2+ Breast Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
- The market growth of HER2+ Breast Cancer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
HER2-positive breast cancer Drugs |
HERCEPTIN (trastuzumab), PERJETA (pertuzumab), BYL719 (alpelisib), SYD985 (Trastuzumab duocarmazine), and Others, and Others |
|
Key Companies |
Novartis, Byondis, Pfizer, Merck Sharp & Dohme, Seagen, Alphamab Oncology, Zymeworks/ALX Oncology and Roche and Many Others |
HER2+ Breast Cancer Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Breast Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers HER2+ Breast Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: Detailed emerging therapies assessment will be provided in the full report of HER2+ Breast Cancer.
HER2+ Breast Cancer Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses HER2+ Breast Cancer key players involved in developing targeted therapeutics.
HER2+ Breast Cancer Clinical Trial Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for HER2+ Breast Cancer emerging therapies.
Learn more about emerging therapies and key companies: HER2-Positive Breast Cancer Pipeline Insight
Reimbursement Scenario in HER2+ Breast Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the HER2+ Breast Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or HER2+ Breast Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the HER2+ Breast Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the HER2+ Breast Cancer Market Report
- The report covers the descriptive overview of HER2+ Breast Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the HER2+ Breast Cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for HER2+ Breast Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the HER2+ Breast Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global HER2+ Breast Cancer market
HER2+ Breast Cancer Market Report Highlights
- In the coming years, the HER2+ Breast Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence HER2+ Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for HER2+ Breast Cancer. The launch of emerging therapies will significantly impact the HER2+ Breast Cancer market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for HER2+ Breast Cancer
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed HER2+ Breast Cancer clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
HER2+ Breast Cancer Report Insights
- Patient Based Market Forecasting
- Therapeutic Approaches
- HER2+ Breast Cancer Pipeline Analysis
- HER2+ Breast Cancer Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
HER2+ Breast Cancer Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- HER2+ Breast Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
HER2+ Breast Cancer Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights:
- What was the HER2+ Breast Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the HER2+ Breast Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest HER2+ Breast Cancer market size during the forecast period (2019-2032)?
- At what CAGR, the HER2+ Breast Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the HER2+ Breast Cancer market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the HER2+ Breast Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of HER2+ Breast Cancer?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
- What is the historical HER2+ Breast Cancer patient pool in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
- What would be the forecasted patient pool of HER2+ Breast Cancer in seven major markets covering the United States, EU4 (Germany, Spain, Italy, and France) and the UK, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about HER2+ Breast Cancer?
- Out of all 7MM countries, which country would have the highest incident population of HER2+ Breast Cancer during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the HER2+ Breast Cancer treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of HER2+ Breast Cancer in the US, Europe, and Japan?
- What are the HER2+ Breast Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of HER2+ Breast Cancer?
- How many therapies are in-development by each company for HER2+ Breast Cancer treatment?
- How many are emerging therapies in mid-stage, and late stage of development for HER2+ Breast Cancer treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HER2+ Breast Cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HER2+ Breast Cancer and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for HER2+ Breast Cancer?
- What are the global historical and forecasted markets of HER2+ Breast Cancer?
Reasons to buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the HER2+ Breast Cancer market
- Organize sales and marketing efforts by identifying the best opportunities for HER2+ Breast Cancer in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the HER2+ Breast Cancer market
- To understand the future market competition in the HER2+ Breast Cancer market
1. Key Insights
2. Executive Summary
3. SWOT Analysis
4. HER2+ Breast Cancer Patient Share at a Glance
4.1. Patient Share (%) Distribution of HER2+ Breast Cancer in 2022
4.2. Patient Share (%) Distribution of HER2+ Breast Cancer in 2032
5. HER2+ Breast Cancer Market Overview at a Glance
5.1. Market Share (%) Distribution of HER2+ Breast Cancer in 2022
5.2. Market Share (%) Distribution of HER2+ Breast Cancer in 2032
6. Disease Background and Overview: HER2+ Breast Cancer
6.1. Introduction
6.2. Causes
6.3. Signs and Symptoms
6.4. Developmental and Clinical Aspects of HER2+ Breast Cancer
6.5. Pathophysiology
6.6. Clinical manifestations in HER2+ Breast Cancer
6.7. Diagnosis
7. Treatment
7.1. Treatment Strategies for HER2+ Breast Cancer
7.2. Treatment Algorithm
8. Patient Journey
9. Epidemiology and Patient Population
9.1 Assumptions and Rationale
9.1.1. Total Incident cases of Breast Cancers in the 7MM (2019–2032)
9.1.2. Incident cases of HER2+ Breast Cancer in the 7MM (2019–2032)
9.1.3. Stage-specific Incidence of of HER2+ of Breast Cancer in the 7MM (2019–2032)
9.1.4. Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the 7MM (2019–2032)
9.1.5. Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the 7MM (2019–2032)
10. Country Wise-Epidemiology of HER2+ Breast Cancer
10.1. The United States
10.1.1. Total Incident cases of Breast Cancer in the United States (2019–2032)
10.1.2. Incident cases of HER2+Breast Cancer in the United States (2019–2032)
10.1.3. Stage-specific Incidences of HER2+ of Breast Cancer in the United States (2019–2032)
10.1.4. Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the United States(2019–2032)
10.1.5. Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the United States (2019–2032)
10.2. EU4 and the UK Countries
10.3.1. Total Incident Cases of Breast Cancer in the EU4 and the UK (2019–2032)
10.3.2. Incident cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
10.3.3. Stage-specific Incidence of HER2+ of Breast Cancer in the EU4 and the UK (2019–2032)
10.3.4. Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the EU4 and the UK (2019–2032)
10.3.5. Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
10.4. Japan
10.4.1. Assumptions and Rationale
10.4.2. Total Incident Cases of Breast Cancer in Japan(2019–2032)
10.4.3. Incident cases of HER2+Breast Cancer in Japan(2019–2032)
10.4.4. Stage-specific Incidence of HER2+ of Breast Cancer in Japan (2019–2032)
10.4.5. Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in Japan (2019–2032)
10.4.6. Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in Japan(2019–2032)
11. Unmet Needs
12. Marketed Product
12.1. Herceptin: Genentech
12.1.1. Product Description
12.1.2. Other Development Activities
12.1.3. Clinical Development
12.1.4. Product Profile
12.1. Enhertu: AstraZeneca and Daiichi Sankyo Company
12.1.1. Product Description
12.1.2. Other Development Activities
12.1.3. Clinical Development
12.1.4. Product Profile
List to be continued…
13. Emerging Drugs
13.1. Key Cross Competition
13.2. BYL719 (alpelisib) : Novartis
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Product Profile
13.3. SYD9854: Byondis
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. ARX788: Ambrx Pharmaceuticals
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
List to be continued in the report….
14. Attribute Analysis
15. HER2+ Breast Cancer: 7 Major Market Analysis
15.1.1. Key Findings
15.1.2. Total 7MM Market Size of HER2+ Breast Cancer
16. The United States Market Outlook
16.1. United States Market Size
16.2. Market Size by Therapies
17. EU4 and the UK Countries: Market Outlook
17.1. Total Market size of HER2+ Breast Cancer in the EU4 and the UK
17..2. Market Size by Therapies
18. Japan: Market Outlook
18.1. Japan market Size
18.1.1. Total Market Size of HER2+ Breast Cancer
18.1.2. Market Size by Therapies
19. Market Access and Reimbursement
20. Market Drivers
21. Market Barriers
22. Appendix
22.1 Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight
List of Table
Table 1: Total Incident cases of Breast Cancer in the United States (2019–2032)
Table 2: Incident cases of HER2+Breast Cancer in the United States (2019–2032)
Table 3: Stage-specific Incidences of HER2+ of Breast Cancer in the United States (2019–2032)
Table 4: Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the United States (2019–2032)
Table 5: Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the United States (2019–2032)
Table 6: Total Incident Cases of Breast Cancer in the EU4 and the UK (2019–2032)
Table 7: Incident cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
Table 8: Stage-specific Incidence of HER2+ of Breast Cancer in the EU4 and the UK (2019–2032)
Table 9: Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the EU4 and the UK (2019–2032)
Table 10: Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
Table 11: Total Incident Cases of Breast Cancer in Japan (2019–2032)
Table 12: Incident cases of HER2+Breast Cancer in Japan (2019–2032)
Table 13: SYD985, Clinical Trials by Recruitment status, 2022
Table 14: SYD985, Clinical Trials by Zone
Table 15: ARX788, Clinical Trials by Recruitment status, 2022
Table 16: ARX788, Clinical Trials by Zone
Table 17: Total 7 Major Market Size in USD, Million (2019–2032)
Table 18: Region wise Market Size in USD, Million (2019–2032)
Table 19: 7MM-Market Size by Therapy in USD, Million (2019–2032)
Table 20: United States Market Size in USD, Million (2019–2032)
Table 21: United States Market Size by Therapy in USD, Million (2019–2032)
Table 22: EU4 and the UK Market Size in USD, Million (2019–2032)
Table 23: EU4 and the UK Market Size by Therapy in USD, Million (2019–2032)
Table 24: Japan Market Size in USD, Million (2019–2032)
Table 25: Japan Market Size by Therapy in USD, Million (2019–2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: Total Incident cases of Breast Cancer in the United States (2019–2032)
Figure 2: Incident cases of HER2+Breast Cancer in the United States (2019–2032)
Figure 3: Stage-specific Incidences of HER2+ of Breast Cancer in the United States (2019–2032)
Figure 4: Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the United States (2019–2032)
Figure 5: Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the United States (2019–2032)
Figure 6: Total Incident Cases of Breast Cancer in the EU4 and the UK (2019–2032)
Figure 7: Incident cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
Figure 8: Stage-specific Incidence of HER2+ of Breast Cancer in the EU4 and the UK (2019–2032)
Figure 9: Subtype-specific Incidence of Breast Cancer [HR+/HER2+ and HR-/HER2+] in the EU4 and the UK (2019–2032)
Figure 10: Total Diagnosed and Treatable Cases of HER2+ Breast Cancer in the EU4 and the UK (2019–2032)
Figure 11: Total Incident Cases of Breast Cancer in Japan (2019–2032)
Figure 12: Incident cases of HER2+Breast Cancer in Japan (2019–2032)
Figure 13: SYD985, Clinical Trials by Recruitment status, 2022
Figure 14: SYD985, Clinical Trials by Zone
Figure 15: ARX788, Clinical Trials by Recruitment status, 2022
Figure 16: ARX788, Clinical Trials by Zone
Figure 17: Total 7 Major Market Size in USD, Million (2019–2032)
Figure 18: Region wise Market Size in USD, Million (2019–2032)
Figure 19: 7MM-Market Size by Therapy in USD, Million (2019–2032)
Figure 20: United States Market Size in USD, Million (2019–2032)
Figure 21: United States Market Size by Therapy in USD, Million (2019–2032)
Figure 22: EU4 and the UK Market Size in USD, Million (2019–2032)
Figure 23: EU4 and the UK Market Size by Therapy in USD, Million (2019–2032)
Figure 24: Japan Market Size in USD, Million (2019–2032)
Figure 25: Japan Market Size by Therapy in USD, Million (2019–2032)
*The list of figures is not exhaustive; the final content may vary